chloride channel; cystic fibrosis; drug discovery; high-throughput screening CYSTIC FIBROSIS (CF) is caused by mutations in a gene coding for a Cl Ϫ channel protein, named CFTR, expressed in epithelial cells of various organs, including lungs, pancreas, sweat glands, liver, and intestine (25) . CFTR, a member of the ATP-binding cassette transporter superfamily (13) , consists of five distinct domains: two membrane-spanning domains, two nucleotide-binding domains (NBDs), and a regulatory domain. ATP binding and possibly hydrolysis at the NBDs are responsible for channel gating, whereas cAMP-dependent phosphorylation of the regulatory domain regulates channel activity (25) . According to the loss-of-function mechanism, CF mutations are grouped into five classes. The most frequent mutation (90% of alleles worldwide; Ref. 1) is the deletion of phenylalanine 508 (F508del) in NBD1. F508del, which belongs to class 2, causes a severe defect in CFTR protein maturation, consisting of retention at the endoplasmic reticulum (ER) level and early degradation by the proteasome system (5, 15) . The F508del-CFTR protein can be partially rescued from the ER by incubating the cells at a permissive temperature (e.g., 27°C; Refs. 4, 5, 12) . This treatment allows the protein to traffic to the plasma membrane. Under these conditions, F508del-CFTR shows a second defect, which consists of reduced channel activity (gating defect; Ref. 4) . Class 3 mutations, such as G1349D and G551D (2, 11) , have normal trafficking but are affected by a gating defect more severe than that of F508del. G551D and G1349D alter two highly conserved glycines in NBD1 and NBD2, respectively.
It has been demonstrated that F508del and class 3 CFTR mutants are druggable targets (7, 14, 28, 32) . Small molecules, called potentiators, are able to acutely enhance mutant CFTR channel activity, possibly by direct interaction. Various classes of potentiators have been described, many of them deriving from high-throughput screenings (28) . Potentiators are able to stimulate channel activity considerably to therapeutically relevant levels (18, 32) . Other types of small molecules, called correctors, are able to improve F508del-CFTR trafficking. However, compared with potentiators, correctors are characterized by a relatively low efficacy, particularly in primary airway epithelial cells from CF patients. For example, rescue of F508del-CFTR function by corr-4a in bronchial epithelial cells achieved only 8% of normal function (19) . The reason for the different efficacy of correctors and potentiators may be different mechanisms of action. A reasonable hypothesis for potentiators postulates that they bind directly to CFTR protein, at the level of NBDs, facilitating their dimerization, which is the prelude to channel opening. For correctors, instead, two different mechanisms of action have been postulated (22) . First, they could be pharmacological chaperones, acting directly on CFTR and thus facilitating its folding and its escape from the ER. This hypothesis implies that correctors should work in any cell type expressing F508del-CFTR. Alternatively, correctors could be regulators of protein homeostasis (proteostasis regulators; Ref. 22) , meaning that they modulate other proteins, involved in CFTR maturation or degradation. In this case, their activity might be dependent on the cell type in which they are tested.
Potentiators and correctors are potentially interesting for the development of effective drugs and as powerful tools for basic research. However, a direct comparison of the molecules found so far by different research groups is lacking. This is important to prioritize chemical scaffolds on the basis of potency and efficacy. In our study, we have analyzed the properties of a series of potentiators and correctors that have been selected and made available to CF investigators by the Cystic Fibrosis Foundation (http://www.cftrfolding.org/CFFTReagents.htm). For this purpose, we have used two different cell models and functional assays.
MATERIALS AND METHODS
Cell culture. Clonal populations of Fischer rat thyroid (FRT) epithelial cells stably coexpressing human CFTR and the high-sensitivity halide-sensing green fluorescent analog yellow fluorescent protein (YFP)-H148Q/I152L (9) were generated as described previously (10) . In brief, FRT cells were first stably transfected with the plasmid pTRACER (Invitrogen) containing the cDNA encoding CFTR (wild type or mutant F508del, G1349D, or G551D) and selected in Zeocin (0.6 mg/ml). Positive clones were then transfected with the plasmid pcDNA3.1 (Invitrogen) containing the cDNA encoding YFP-H148Q/ I152L and selected in G418 (0.75 mg/ml). A549 cell clones stably coexpressing human F508del-CFTR and YFP-H148Q/I152L were generated similarly. FRT cells were cultured in Coon's modified Ham's F-12 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. A549 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)-Ham's F-12 (1:1) medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. For fluorescence assays of CFTR activity, FRT and A549 cells were plated (50,000 cells/well) on clear-bottomed 96-well microplates (Corning Life Sciences, Acton, MA). For Ussing chamber experiments, FRT cells were seeded into Snapwell permeable supports (Corning Life Sciences) at 500,000 cells per insert. Polarized preparations of human bronchial epithelial (HBE) cells were generated on the same type of Snapwell inserts as described previously (8) . In brief, bronchi from CF patients, obtained after lung transplant, were digested overnight with protease XIV to detach surface epithelial cells. Cells were initially grown in flasks with a serum-free medium that allowed cell proliferation. Thereafter, the cells were plated at high density on the permeable supports. At this stage, the medium was replaced with a mixture of DMEM-Ham's F-12 medium supplemented with 2% fetal calf serum and various hormones to favor cell differentiation (8) .
Compounds. The Cystic Fibrosis Foundation Therapeutics (CFFT) CFTR modulator panel (see Fig. 1 Ϫ influx rate, the final 11 s of the data for each well were fitted with an exponential function to extrapolate initial slope (dF/dt).
Transepithelial current measurements. Short-circuit current measurements were performed on the same FRT cells coexpressing CFTR and YFP-H148Q/I152L used for the fluorescence assay for CFTR activity. Experiments on FRT cells were performed on days 7-9 after plating. Snapwell inserts were mounted in a self-contained Ussing chamber system (vertical diffusion chamber; Corning Life Sciences). Transepithelial currents were measured with a transepithelial Cl Ϫ gradient. Accordingly, the basolateral solution contained (in mM) 130 NaCl, 2.7 KCl, 1.5 KH 2PO4, 1 CaCl2, 0.5 MgCl2, 10 Na-HEPES, pH 7.3, and 10 glucose. For the apical side, this solution was modified by replacing half the NaCl with sodium gluconate and increasing CaCl 2 to 2 mM to compensate for calcium buffering caused by gluconate. For human airway epithelial cells, both apical and basolateral chambers contained (in mM) 126 NaCl, 0.38 KH 2PO4, 2.1 K2HPO4, 1 MgSO4, 1 CaCl2, 24 NaHCO3, and 10 glucose. During experiments, solutions in both chambers were continuously bubbled with air (FRT cells) or with 5% CO 2 in air (airway epithelial cells). The hemichambers were connected to DVC-1000 voltage clamps (World Precision Instruments, Sarasota, FL) via Ag/AgCl electrodes and 1 M KCl agar bridges. Transepithelial currents were digitized with PowerLab 4/25 data acquisition systems and stored on Macintosh computers. All measurements were performed at 37°C.
Immunoprecipitation and Western blots. Cells grown on 100-mmdiameter dishes were lysed in lysis buffer (20 mM HEPES pH 7, 150 mM NaCl, 1 mM EGTA, 1% IGEPAL) containing Complete protease inhibitor (Roche). After preclearing of lysates with Pansorbin (Calbiochem), CFTR was immunoprecipitated in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing 2 mM MgATP, with a mouse monoclonal anti-CFTR COOH-terminal antibody (24-1, R&D Systems) and Pansorbin. The immunoprecipitates were subjected to SDS-PAGE and analyzed by Western blotting. Proteins were immunodetected by a mouse monoclonal anti-CFTR antibody (M3A7, Millipore) followed by horseradish peroxidase (HRP)-conjugated anti-mouse IgG and visualized by chemiluminescence with the LiteAblot Turbo kit (Euroclone). Direct recording of the chemiluminescence was performed with the Molecular Imager ChemiDoc XRS System and quantification with ImageJ software (National Institutes of Health).
Data analysis. Data for all experiments are presented as representative traces or as means Ϯ SE. Statistical analyses were done with analysis of variance (ANOVA) followed by Tukey's multiple comparison test.
RESULTS
The CFFT CFTR modulator panel consists of 4 correctors (C1-C4) and 10 potentiators (P1-P10), whose identity is reported in Fig. 1 . Besides this panel, we included three other potentiators, belonging to the 1,4-dihydropyridine (DHP) family, that we identified previously (20, 21) . Felodipine is a DHP commonly used as an antihypertensive drug that is also strongly effective as a CFTR potentiator (20) . DHP-229 and DHP-256 are optimized DHPs with an improved selectivity for CFTR versus voltage-dependent Ca 2ϩ channels, the pharmacological target of antihypertensive DHPs (21) . All compounds were tested on FRT and A549 cells expressing the F508del-CFTR protein. Figure 2 shows the data from the potentiator assay. Cells were previously incubated at 27°C for 24 h to rescue the mutant protein from the ER. Cells were exposed to test compounds plus forskolin for 25 min before the assay and then transferred to the plate reader for the YFP functional assay. Addition of I Ϫ started the YFP fluorescence quenching. Most potentiators strongly increased the rate of I Ϫ influx, indicating enhanced CFTR activity ( Fig. 2A) . We tested the potentiators at different concentrations to assess potency and maximal effect (Fig. 2B) . Most of the compounds behaved similarly in both FRT and A549 cells. Efficacy was equivalent for almost all compounds, and comparable to that of the reference compound genistein (P6) (Fig. 2C) . The exceptions were P8, P9, and P10, which had partial activity in one or both cell types. In particular, P9 was devoid of activity in A549 cells. The order of potency was nearly maintained in the two cell lines. P2 and P3 were the most potent compounds, K a being in the range of 100 -400 nM. On the other hand, P6 (genistein) and P10, with a half-effective concentration of ϳ15 M, were consistently the least potent molecules. In general, there was a good linear correlation between potency in FRT and in A549 cells (Fig. 2D) . Interestingly, the K a values for several potentiators in A549 cells were two to five times higher than those in FRT cells.
Potentiators were also tested on FRT cells expressing the G1349D and the G551D mutants with the YFP assay (Fig. 3) . As expected, CFTR activity in G551D cells was undetectable despite the use of a maximal forskolin concentration (Fig. 3A) . In contrast, the gating defect of the G1349D mutant was less severe, allowing a significant cAMP-activated anion transport. CFTR activity in G551D and G1349D cells was strongly stimulated in the presence of potentiators (Fig. 3A) . Doseresponse relationships showed various levels of potency and efficacy (Fig. 3B ). Some compounds (P1, P2, P5, P6, felodipine, and DHP-256) were maximally effective on both mutants (Fig. 3C) . Other compounds showed partial activity, particularly on G551D cells. Actually, P8, P9, and P10 were completely inactive in this mutant. Interestingly, the order of potency for active potentiators in G551D and G1349D correlated well with the order of potency in F508del (Fig. 3D) . However, the K a values for G551D were consistently 5-10 times higher than those for G1349D and F508del.
To evaluate the activity of correctors, we incubated FRT and A549 cells expressing F508del with test compounds for 24 h and then performed the YFP assay. Cells were acutely stimulated with forskolin plus genistein to maximize CFTR activity. The representative traces in Fig. 4A show that correctors significantly increase anion transport. This response is not due to a "potentiator-like" activity because acute treatment with these compounds was ineffective (not shown). The doseresponse relationships in Fig. 4B show the net effect of correctors. Compounds C1-C4 act in the low micromolar range by increasing CFTR activity two to four times relative to vehicletreated cells. C4 was the most effective compound. Others, particularly C1 and C3, showed a peak activity followed by a decrease at higher concentrations. To verify whether the extent of correction is modified by the acute stimulation with the potentiator (genistein), we also performed experiments in which the cells were stimulated with forskolin alone (Fig. 4C) . We found that the relative increase in CFTR activity elicited by long-term incubation with correctors is not modified by absence/presence of the potentiator. For example, C4 increases F508del-CFTR activity by 3.4-fold and 3.8-fold in the absence and presence of genistein, respectively, in FRT cells and by 3.1-fold in both the absence and the presence of genistein in A549 cells (Fig. 4C) .
To possibly identify novel correctors, we screened the Spectrum library (containing 2,000 compounds, with a high representation of approved drugs) and a set of 394 individually collected approved drugs. All compounds were tested individually at 5 and 20 M on both FRT and A549 cells. Some drugs, including steroids (flunisolide, flumethasone, desoximetasone) and benzimidazoles (flubendazole, fenbendazole, mebendazole) were active only in FRT cells. Other compounds, such as daunorubicin, doxorubicin, epirubicin, idarubicin, and others, were active instead in A549 cells. The only compound from the library having activity on both cell types was plicamycin; however, this compound failed subsequent validation with the Ussing chamber technique (not shown). Such findings are summarized in Table 1 and in Fig. 4D , where the activity of each compound in FRT cells is plotted versus the activity of the same compound in A549 cells. Except for previous correctors, such as C1-C4 and analogs, and plicamycin, all other molecules were effective in one cell line only. All active compounds were tested in null FRT and A549 cells. We found no activity, thus indicating that they were effective on F508del-CFTR and not on an endogenous channel or transporter. To further validate our results, we tested putative correctors at different concentrations in FRT and A549. An example is shown for flubendazole in Fig. 4B . This benzimidazole generated a dosedependent effect in FRT cells but was devoid of activity at all concentrations in A549 cells. 
F508del, deletion of phenylalanine 508; FRT, Fischer rat thyroid cells; HBE, human bronchial epithelial cells. Ϫ, No rescue observed; ϩ, 1.1-to 1.9-fold rescue; ϩϩ, 2-to 2.9-fold rescue; ϩϩϩ, Ն3-fold rescue; n.d., not determined.
We looked for the possibility of enhancing F508del-CFTR rescue by using a combination of treatments. C3 and C4 together enhanced CFTR activity by 4.5 (FRT cells) and 6 (A549 cells) times, significantly better than either corrector alone (Fig. 5A) . Combination of C3 or C4 with low temperature (27°C) also caused an additive effect on both cell types. Flubendazole markedly enhanced the effect of correctors, particularly of C4, in FRT cells. The additive effect induced by combination of treatments was confirmed in short-circuit current recordings in FRT cells (Fig. 5B) . In contrast, flubendazole was without effect on A549 cells, even when added together with other compounds or low temperature (Fig. 5A) .
The efficacy of combination treatments was also confirmed at the biochemical level by determining the pattern of electrophoretic mobility of the CFTR protein. Wild-type CFTR is detected in Western blots as two bands, named B and C, of nearly 150 and 170 kDa, respectively. Band B corresponds to partially glycosylated CFTR residing in the ER. Band C is instead the mature fully processed CFTR that has passed through the Golgi. The prevalent form in cells expressing wild-type CFTR is band C, as also shown for A549 cells in Fig. 6 . In contrast, cells expressing F508del-CFTR have mostly band B, in agreement with the severe trafficking defect caused by the mutation. Treatment of F508del cells at 37°C with either C3 or C4 did not significantly enhance the relative abundance of mature CFTR (Fig. 6) , i.e., the ratio of band C intensity to that of total CFTR (band C ϩ band B). However, combined treatment with both compounds elicited a significant increase in relative band C intensity compared with vehicle alone or compared with treatment with a single compound. Interestingly, cell incubation at low temperature significantly enhanced the effect of corrector C4 relative to vehicle alone, but not that of C3 (Fig. 6) . C4 also had an effect on wild-type CFTR. This effect consisted of an increase in total CFTR levels without altering the band C-to-band C ϩ band B ratio. Correctors were tested on bronchial epithelial cells derived from a CF patient homozygous for the F508del mutation (Fig. 7) . C3 and C4 caused a significant but very modest increase of the CFTRdependent current compared with low-temperature incubation, as evident from the amplitude of the inhibition caused by CFTR inh -172. In contrast, flubendazole was totally ineffective ( Fig. 7B ; see also Table 1 for activity of other compounds on HBE cells). CFTR rescue was not enhanced by combining C3 and C4 together or by combining each compound with low-temperature incubation.
DISCUSSION
The aim of our study was to compare the efficacy and potency of various compounds that have been identified as correctors and potentiators of mutant CFTR. In particular, we wanted to assess the influence of cell background in determining the response of CFTR to the different modulators. In general, most potentiators worked similarly in the two cell lines that we used to express F508del-CFTR. The relative efficacy of each compound was comparable between FRT and A549 cells and close to maximum. The exceptions were P8, P9, and P10, with partial and inconsistent activity between the two cell lines. In particular, P9 was almost maximally effective in FRT cells and essentially ineffective in A549 cells. Potentiators showed a similar order of potency in the two cell models, with P2 and P3 (phenylglycine PG-01 and sulfonamide SF-03; Ref. 18 ) and P6 and P10 (genistein and the isoxazole UCCF-152; Refs. 6, 23) being the most potent and least potent compounds, respectively.
Potentiators were also tested on two classical CF mutations belonging to class 3 (gating defect), namely, G551D and G1349D. Such mutations are particularly interesting because they cause a drastic reduction in CFTR activity (with G551D being the most severe mutation) and because they involve two highly conserved glycine residues in the first and second NBDs, respectively. Many potentiators were effective in enhancing the activity of the two mutants, with the important exception, as also observed for F508del, of P8, P9, and P10. In particular, the G551D mutant was almost totally insensitive to these three compounds. Other potentiators were also less effective in activating G551D, such as the sulfonamide P3. In general, the order of potency of the active potentiators was similar for G551D, G1349D, and F508del. Although the order of potency was maintained, the K a values for G551D were consistently 5-10 times higher than those of the other two mutants. This finding is consistent with previous reports indicating the mutation of glycine 551 as an important element in decreasing the affinity of potentiators to their binding site (16, 17, 31) .
Our findings suggest that all potentiators having activity on G551D, G1349D, and F508del (P1-P7 and DHPs) act with the same mechanism of action, possibly through binding to the same site on CFTR protein. A direct mechanism of action would explain the small influence of cell background on potentiator activity In contrast, P8, P9, and P10 may represent a different class of compounds acting not as true CFTR potentiators but with a more indirect mechanism. If so, these scaffolds should not be considered in the modeling of potentiator binding to CFTR protein and in the design of pharmacophores. In contrast to potentiators, corrector activity is strongly influenced by cell background. We found that correctors previously identified by high-throughput screenings such as C3 and C4 (VRT-325 and corr-4a; Refs. 19, 27) were effective in both FRT and A549. However, other putative correctors were effective only in one or the other cell line. As an example, flubendazole was particularly effective in FRT cells in rescuing the activity of F508del-CFTR, with an efficacy comparable to that of C3 and C4. Conversely, it was completely ineffective in A549 cells and in primary cultures of bronchial epithelial cells.
Usually, the activity of correctors on F508del-CFTR is evaluated by acutely stimulating the cells with a cAMP agonist (forskolin or a membrane-permeant cAMP analog) plus a potentiator (often genistein) at a maximal concentration (19) . We asked whether treatment with correctors changes the relative activity elicited by cAMP stimulation alone compared with the total activity obtained by the addition of the potentiator. Our experiments show that the relative extent of F508del correction is not significantly altered by the presence/absence of the potentiator. In other words, the percent increase in activity caused by the potentiator is not altered by previous correction treatment.
Another concept emerging from our study is the additive effect generated by combinations of rescue maneuvers (e.g., two correctors together or a corrector at low temperature). These findings suggest that a single treatment is far from reaching full rescue of F508del from the ER. Indeed, single treatments have very little effect when studied at the biochemical level. For example, compounds such as corr-4a (C4) cause a very small increase in band C intensity, unless combined with C3 or low temperature. However, combinations of treatments, although being more effective, do not increase band C to levels comparable to those of wild-type CFTR. These results suggest the presence of multiple sequential checkpoints for F508del-CFTR processing, as pointed out by others previously (22, 24, 26, 30) . For example, it has been shown that F508del-CFTR is targeted early for degradation at the cotranslational and posttranslational levels by separate ubiquitin ligases (26) . Other checkpoints may also exist at later stages in the ER. Furthermore, F508del-CFTR is also rapidly internalized from the plasma membrane at a rate higher than the wild-type protein (24) . Therefore, there are multiple ways through which a corrector may act. It is also expected that compounds having different mechanisms of action generate additive/synergistic effects when added together.
A disappointing finding in our study is the discordant activity of putative correctors when tested in different cell systems, including primary cultures of bronchial epithelial cells. Our results show that the activity of a compound in one cell line expressing F508del-CFTR is poorly predictive of activity in the native tissue. It is possible that the contribution of the various mechanisms controlling CFTR maturation, trafficking, and degradation is different between cell models. Consequently, pharmacological rescue of F508del-CFTR may also differ strongly when a given compound is tested in different cell types. Another source of variability may also arise from cell culture conditions that may differ among various laboratories. For example, serum type and concentration may affect cell behavior and compound stability/solubility.
The practical implications of our study are that putative correctors identified by high-throughput screening in a given cell model need to be rapidly validated in primary airway epithelial cells. This conclusion may also be relevant for other types of approaches such as rescue by gene silencing with small interfering RNA (siRNA). Indeed, the function of a protein whose silencing in a recombinant cell line leads to significant F508del-CFTR rescue may not be similarly effective in a native cell. However, testing several putative correctors or other types of treatments on primary cultures is impractical. Our work suggests that a counterscreening on a second cell line expressing F508del-CFTR may be useful to categorize compounds having a more general mechanism of action versus those with more cell-specific activity. This information may be useful in the prioritization and development of compounds.
